NEW YORK (GenomeWeb) – Personal Genome Diagnostics said today that its PGDx Elio Plasma Resolve liquid biopsy assay has received CE marking.
The in vitro diagnostic uses next-generation sequencing to detect single-nucleotide variants, small insertions and deletions, amplifications, rearrangements, and microsatellite instability in circulating cell-free DNA isolated from plasma samples to guide therapy selection for cancer patients. PGDx also markets a tissue-based version of the test.